Videos

Debra Goff, PharmD, shares how the "Train-the-Trainer" program was implemented in South Africa with Pablo J. Sánchez, MD, and Pavel Prusakov, PharmD.

Investigators with The University of Texas Health Science Center embarked on a study to determine whether HIV disclosure at the emergency department should be based on preliminary results.

Samuel L. Aitken, PharmD, MPH, discusses the article he wrote with Dr. Sarah L. Spitznogle for the October issue of Contagion® evaluating the role of new β-lactam agents for uncommon pathogens.

Jason Schafer, PharmD, MPH, BCPS AQ-ID, previews the October issue featuring an article on rapid initiation of antiretroviral therapy.

Pablo J. Sánchez, MD, discusses the need for NICU stewardship with Debra Goff, PharmD, and Pavel Prusakov, PharmD.

Helen Chu, MD, MPH, discussed the "Seattle Flu Study" with Contagion at IDWeek 2019.

Elizabeth Hirsch, PharmD, previews her piece with Mélanie Mahoney, PharmD student, on 2019 updates to CLSI breakpoints.

Hermione Hurley, MD, MCBhB, discusses the intersection of substance use disorder and infectious disease.

Jason Pogue, PharmD, BCPS, BCIDP, shares that SIDP will become the fifth partner in IDWeek, joining the Infectious Diseases Society of America, the HIV Medicine Association, the Pediatric Infectious Diseases Society, and the Society for Healthcare Epidemiology of America.

Debra Goff, PharmD, discusses why it is critical to engage dentists and orthopedic surgeons in antimicrobial stewardship activities.

Elizabeth Hirsch, PharmD, and Elizabeth Smith, PharmD candidate, discuss fosfomycin susceptibility testing.

Minh-Hong Nguyen, MD, discusses rezafungin as a potential treatment option for intra-abdominal candidiasis.

Steven Tong, PhD, discusses the benefit of investigator-initiated studies.

Monica V. Mahoney, PharmD, discusses how shorter courses of therapy are just as effective as longer courses of therapy.

Leslie Tari, PhD, discusses the treatment and prevention of influenza.

László Majoros, MD, PhD, discusses how nearly all invasive fungal infections are being treated with echinocandins.

Tristan Ferry, MD, PhD, discusses bacteriophage therapy as an alternative treatment for certain patients.

Marin Kollef, MD, discusses what makes the 3-gram dose regimen of ceftolozane/tazobactam unique.

Glenn Tillotson, PhD, discusses possible avenues for future research on gram-negative skin infections and inappropriate empiric therapy.

Matthew Girgis, PharmD, PGY-2, discusses why it's advantageous to decrease patient exposure to vancomycin.

We asked providers in the field why they pursued a career in infectious disease.

Glenn Tillotson, PhD, explains how inappropriate empiric therapy can drive poor outcomes.

Experts provide community physicians treating HIV with practical advice for screening, diagnosing, and managing patients with HIV.

Kimberly Claeys, PharmD, discusses the need for more data on rapid diagnostics for gram-negative bloodstream infections.

Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, previews his editor-in-chief letter for the June issue.

Ryan K. Shields, PharmD, MS, Contagion®'s Multidrug-Resistant Infections Section Editor, previews the upcoming June issue.

Section Editor, Monica Mahoney, PharmD, shares a preview of the June issue of Contagion.

Thomas Lodise, PharmD, PhD, discusses why "time to clinical response" is a valuable metric to use in clinical studies.